Breast imaging software developer Volpara Solutions lauds the results of the Dense Tissue and Early Breast Neoplasm Screening (DENSE) trial recently published in the New England Journal of Medicine.
The Dutch trial found using supplemental MRI screening in women with extremely dense breast tissue and normal mammograms resulted in significantly fewer interval cancers than using mammography alone.
Volpara provided the Dutch researchers with the VolparaDensity software used to automatically and objectively assess breast density in the DENSE trial. Women with extremely dense breast tissue above a Volpara volumetric breast density of 15.5% -- the densest BI-RADS category -- benefited from MRI supplemental screening.
The trial provides a clear template for how organized screening programs can use volumetric breast density percentage to triage women who are at greatest risk of developing interval cancers, according to Volpara.
